Patents by Inventor Bradley M. Savall

Bradley M. Savall has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Azabenzimidazoles and their use as AMPA receptor modulators
    Patent number: 12145934
    Abstract: Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, Also provided herein are pharmaceutical compositions comprising compounds of Formula (I) and methods of using compounds of Formula (I).
    Type: Grant
    Filed: October 17, 2022
    Date of Patent: November 19, 2024
    Assignee: Janssen Pharmaceutica NV
    Inventors: Michael K. Ameriks, Gang Chen, Bradley M. Savall, Devin M. Swanson, Wei Zhang, Dongpei Wu
  • Azabenzimidazoles and their use as AMPA receptor modulators
    Patent number: 12139485
    Abstract: Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, Also provided herein are pharmaceutical compositions comprising compounds of Formula (I) and methods of using compounds of Formula (I).
    Type: Grant
    Filed: October 17, 2022
    Date of Patent: November 12, 2024
    Assignee: Janssen Pharmaceutica NV
    Inventors: Michael K. Ameriks, Gang Chen, Bradley M. Savall, Devin M. Swanson, Wei Zhang, Dongpei Wu
  • AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS
    Publication number: 20230114165
    Abstract: Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, Also provided herein are pharmaceutical compositions comprising compounds of Formula (I) and methods of using compounds of Formula (I).
    Type: Application
    Filed: October 17, 2022
    Publication date: April 13, 2023
    Inventors: Michael K. Ameriks, Gang Chen, Bradley M. Savall, Devin M. Swanson, Wei Zhang, Dongpei Wu
  • AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS
    Publication number: 20230110576
    Abstract: Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, Also provided herein are pharmaceutical compositions comprising compounds of Formula (I) and methods of using compounds of Formula (I).
    Type: Application
    Filed: October 17, 2022
    Publication date: April 13, 2023
    Inventors: Michael K. Ameriks, Gang Chen, Bradley M. Savall, Devin M. Swanson, Wei Zhang, Dongpei Wu
  • Azabenzimidazoles and their use as AMPA receptor modulators
    Patent number: 11312712
    Abstract: Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, Also provided herein are pharmaceutical compositions comprising compounds of Formula (I) and methods of using compounds of Formula (I).
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: April 26, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: Michael K. Ameriks, Cynthia G. B. Berry, Gang Chen, Suchitra Ravula, Bradley M. Savall, Devin M. Swanson, Dongpei Wu, Wei Zhang
  • AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS
    Publication number: 20210284641
    Abstract: Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, Also provided herein are pharmaceutical compositions comprising compounds of Formula (I) and methods of using compounds of Formula (I).
    Type: Application
    Filed: May 19, 2021
    Publication date: September 16, 2021
    Applicant: Janssen Pharmaceutica NV
    Inventors: Michael K. Ameriks, Cynthia G.B. Berry, Gang Chen, Fabrice Loic Jourdan, Terry Patrick Lebold, David Wei Lin, Miguel Angel Pena Piñon, Suohitra Ravula, Bradley M. Savall, Devin M. Swanson, Dongpei Wu, Wei Zhang
  • Benzimidazolone and benzothiazolone compounds and their use as AMPA receptor modulators
    Patent number: 10611730
    Abstract: Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, Also provided herein are pharmaceutical compositions comprising compounds of Formula (I) and methods of using compounds of Formula (I).
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: April 7, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Michael K. Ameriks, Suchitra Ravula, Devin M. Swanson, Bradley M. Savall
  • Indolone compounds and their use as AMPA receptor modulators
    Patent number: 10604484
    Abstract: Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, Also provided herein are pharmaceutical compositions, comprising compounds of Formula (I), and methods of using compounds of Formula (I).
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: March 31, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Michael K. Ameriks, Suchitra Ravula, Bradley M. Savall, Devin M. Swanson, Jeannie M. Ziff, Brock T. Shireman
  • Imidazopyrazines and pyrazolopyrimidines and their use as AMPA receptor modulators
    Patent number: 10513523
    Abstract: Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, Also provided herein are pharmaceutical compositions, comprising compounds of Formula (I), and methods of using compounds of Formula (I).
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: December 24, 2019
    Assignee: Janssen Pharmaceutica NV
    Inventors: Michael K. Ameriks, Bradley M. Savall, Devin M. Swanson, Dongpei Wu
  • BENZIMIDAZOLONE AND BENZOTHIAZOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS
    Publication number: 20190092735
    Abstract: Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, Also provided herein are pharmaceutical compositions comprising compounds of Formula (I) and methods of using compounds of Formula (I).
    Type: Application
    Filed: April 28, 2016
    Publication date: March 28, 2019
    Applicant: Janssen Pharmaceutica NV
    Inventors: Michael K. Ameriks, Suchitra Ravula, Devin M. Swanson, Bradley M. Savall
  • AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS
    Publication number: 20180118740
    Abstract: Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, Also provided herein are pharmaceutical compositions comprising compounds of Formula (I) and methods of using compounds of Formula (I).
    Type: Application
    Filed: April 28, 2016
    Publication date: May 3, 2018
    Applicant: Janssen Pharmaceutica NV
    Inventors: Michael K. Ameriks, Cynthia G. B. Berry, Gang Chen, Fabrice Loic Jourdan, Terry Patrick Lebold, David Wei Lin, Miguel Angel Pena Piñon, Suchitra Ravula, Bradley M. Savall, Devin M. Swanson, Dongpei Wu, Wei Zhang
  • IMIDAZOPYRAZINES AND PYRAZOLOPYRIMIDINES AND THEIR USE AS AMPA RECEPTOR MODULATORS
    Publication number: 20180118751
    Abstract: Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, Also provided herein are pharmaceutical compositions, comprising compounds of Formula (I), and methods of using compounds of Formula (I).
    Type: Application
    Filed: April 28, 2016
    Publication date: May 3, 2018
    Applicant: Janssen Pharmaceutica NV
    Inventors: Michael K. Ameriks, Bradley M. Savall, Devin M. Swanson, Dongpei Wu
  • INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS
    Publication number: 20180118683
    Abstract: Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, Also provided herein are pharmaceutical compositions, comprising compounds of Formula (I), and methods of using compounds of Formula (I).
    Type: Application
    Filed: April 28, 2016
    Publication date: May 3, 2018
    Applicant: Janssen Pharmaceutica NV
    Inventors: Michael K. Ameriks, Suchitra Ravula, Bradley M. Savall, Devin M. Swanson, Jeannie M. Ziff, Brock T. Shireman